Classical galactosaemia is an autosomal recessive disorder of galactose metabolism due to a deficiency of the enzyme galactose-lphosphate uridyl transferase (transferase). Most questionnaire. In addition, those specialist laboratories who provide a service for transferase assay were contacted annually for details of cases of galactosaemia that they had confirmed during the study period.
Results
During the period of the study, from 1 January 1988-31 December 1990, 112 cases of suspected galactosaemia were notified. Of these, 58 were confirmed to have classical galactosaemia with absent transferase activity. The diagnosis was strongly suspected in two additional cases who were subsequently included in the study. One of these died of Escherichia coli septicaemia at 4 days of age. Although transferase assay was not performed on this patient, the transferase activity of both parents was within the range of heterozygotes. In the other case, transferase assay was deferred because an exchange transfusion had been done for jaundice and the diagnosis was not subsequently confirmed. The clinical presentation and response to withdrawal of galactose from the diet, however, was consistent with a diagnosis of galactosaemia. Five children with other disorders of galactose metabolism, apart from classical galactosaemia, were also detected by screening laboratories. These were Duarte/galactosaemia compound heterozygotes (two patients), uridine diphosphogalactose-4-epimerase deficiencies (two patients), and galactokinase deficiency (one patient).
Of the 60 patients included in the study, 56 were white. There was one death in this group, that of the patient referred to earlier who died from E coli septicaemia at 4 days. Three siblings of the study patients died of liver disease around 6 weeks of age and were presumed affected. Two came from areas that were being screened at the time of their birth, but it could not be confirmed that neonatal screening had been performed in these cases. The other came from an area not screening for galactosaemia. Age in days Age at introduction ofgalactose free diet. significance can be attached to the fact that during the study period only one death occurred in the non-screened group because there was no means of ascertaining all the deaths from galactosaemia. It is notable, however, that this death occurred at 4 days of age and is, therefore, unlikely to have been prevented by screening. The sibling data indicates a lower mortality generally among families in the study compared with the study referred to earlier,' with only one sibling death, presumed due to galactosaemia, in the nonscreened group. On the other hand two sibling deaths were identified in families that were resident in screened populations at the time of death. Although screening might reduce neonatal morbidity overall, the incidence of severe symptoms was no higher in the non-screened group than in the screened group. Moreover, recent work has shown that long term outlook is not influenced by the severity of neonatal symptoms,4 and only if treatment is started after the 65th day is there any significant effect on developmental progress. Treatment was started after this period in two out of 46 babies in the non-screened group.
The accepted criteria for the introduction of a screening programme have only partially been met in the case of galactosaemia. Although-screening should lead to earlier diagnosis this has no long term consequences apart from in a minority of cases. These cases should all be under paediatric care and the symptoms point to galactosaemia as a possible diagnosis. Although the incidence in the UK was higher than previously supposed,6 and the higher incidence in the Republic of Ireland was confirmed, galactosaemia is a relatively rare disease and screening for it should not take a high priority. The negative effects of a screening programme have also to be considered. It may reduce clinical vigilance and, in consequence lead to the death of a child who becomes acutely ill at a very early age before the screening result is available. A false negative result, which should occur very infrequently but did occur during the study, may delay consideration of the diagnosis with possible harmful consequences.
It is concluded from the study that there is no real justification to introduce galactosaemia screening on a wider scale within the UK. Countries that do not screen for the disease should, however, continue to maintain a high level of awareness of the disease. This is particularly important when there is known to be an increased risk in the family, and it applies even in areas that have a screening programme. Early in the neonatal period, patients may present with a fuIminating septicaemic illness with encephalopathy, jaundice, and coagulopathy and if the patient dies there is a risk that the underlying metabolic disorder will not be recognised. More commonly the patients present with jaundice, vomiting, feeding difficulties, and hepatomegaly. Those who present later have a more chronic illness characterised by failure to thrive, with feeding difficulties, development delay, fits, and renal tubular disease. Jaundice may be less prominent but if there is any suspicion of galactosaemia, cataracts should always be sought.
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